Your browser doesn't support javascript.
loading
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden, Mary J; Zwarthoff, Seline A; Arends, Roel J; Reinieren-Beeren, Inge M J; Paradé, Marc C B C; Driessen-Engels, Lilian; de Laat-Arts, Karin; Damming, Désirée; Santegoeds-Lenssen, Ellen W H; van Kuppeveld, Daphne W J; Lodewijks, Imke; Olsman, Hugo; Matlung, Hanke L; Franke, Katka; Mattaar-Hepp, Ellen; Stokman, Marloes E M; de Wit, Benny; Glaudemans, Dirk H R F; van Wijk, Daniëlle E J W; Joosten-Stoffels, Lonnie; Schouten, Jan; Boersema, Paul J; van der Vleuten, Monique; Sanderink, Jorien W H; Kappers, Wendela A; van den Dobbelsteen, Diels; Timmers, Marco; Ubink, Ruud; Rouwendal, Gerard J A; Verheijden, Gijs; van der Lee, Miranda M C; Dokter, Wim H A; van den Berg, Timo K.
Afiliação
  • van Helden MJ; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Zwarthoff SA; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Arends RJ; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Reinieren-Beeren IMJ; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Paradé MCBC; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Driessen-Engels L; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • de Laat-Arts K; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Damming D; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Santegoeds-Lenssen EWH; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van Kuppeveld DWJ; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Lodewijks I; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Olsman H; Sanquin Research, Amsterdam, The Netherlands.
  • Matlung HL; Sanquin Research, Amsterdam, The Netherlands.
  • Franke K; Sanquin Research, Amsterdam, The Netherlands.
  • Mattaar-Hepp E; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Stokman MEM; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • de Wit B; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Glaudemans DHRF; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van Wijk DEJW; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Joosten-Stoffels L; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Schouten J; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Boersema PJ; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van der Vleuten M; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Sanderink JWH; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Kappers WA; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van den Dobbelsteen D; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Timmers M; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Ubink R; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Rouwendal GJA; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Verheijden G; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van der Lee MMC; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • Dokter WHA; Byondis BV, Nijmegen, Gelderland, The Netherlands.
  • van den Berg TK; Byondis BV, Nijmegen, Gelderland, The Netherlands Timo.vandenBerg@byondis.com.
J Immunother Cancer ; 11(4)2023 04.
Article em En | MEDLINE | ID: mdl-37068796
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno CD47 / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno CD47 / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article